Peter Bader, Claudia Rossig, Martin Hutter, Francis Ayuketang Ayuk, Claudia D Baldus, Veit L Bücklein, Halvard Bonig, Gunnar Cario, Hermann Einsele, Udo Holtick, Christian Koenecke, Shahrzad Bakhtiar, Annette Künkele, Roland Meisel, Fabian Mueller, Ingo Müller, Olaf Penack, Eva Rettinger, Martin G Sauer, Paul-Gerhardt Schlegel, Jan Soerensen, Arend von Stackelberg, Brigitte Strahm, Tobias Feuchtinger, Julia Hauer, Andrea Jarisch
Patients with precursor B cell acute lymphoblastic leukemia (pB-ALL) who have relapsed subsequent to allogeneic stem cell transplantation (alloHSCT), have relapsed more than once, or are resistant upfront have a dismal prognosis. CD19-targeted CAR-T cells have evolved as potent immune therapies. Tisagenlecleucel (Tisa-cel) is a commercial autologous CD19-directed CAR-T cell product. We performed a retrospective study inviting all CAR-T cell centers in Germany to participate. Eighty-one patients with pB-ALL were included...
January 6, 2023: Blood Advances